Atlas Trials

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

Clinical trial NCT02642458 · UNKNOWN

Trial details

NCT number
NCT02642458
Sponsor
University Hospital Tuebingen
Status
UNKNOWN
Study type
OBSERVATIONAL
Metastatic Breast Cancer
Start date
2016-03-01
Primary completion
2020-03-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.